Holen Sie sich die Stockscreener-App
36.22
0.52%
-0.19
Schlusskurs vom Vortag:
$36.41
Offen:
$36.48
24-Stunden-Volumen:
635.36K
Relative Volume:
0.82
Marktkapitalisierung:
$2.09B
Einnahmen:
$772.53M
Nettoeinkommen (Verlust:
$180.90M
KGV:
11.67
EPS:
3.1024
Netto-Cashflow:
$258.73M
1W Leistung:
-6.04%
1M Leistung:
-6.72%
6M Leistung:
+2.87%
1J Leistung:
-6.02%
1-Tages-Spanne:
$36.10
$37.08
1-Wochen-Bereich:
$34.68
$39.40
52-Wochen-Spanne:
$25.52
$40.93
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Firmenname
Harmony Biosciences Holdings Inc
Sektor
Branche
Telefon
(484) 539-9800
Adresse
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Vergleichen Sie HRMY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
36.22 | 2.10B | 772.53M | 180.90M | 258.73M | 3.1024 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-09-10 | Eingeleitet | UBS | Buy |
| 2024-06-21 | Eingeleitet | Citigroup | Buy |
| 2024-01-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-09-25 | Herabstufung | Goldman | Neutral → Sell |
| 2023-09-07 | Eingeleitet | Berenberg | Buy |
| 2023-04-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-14 | Hochstufung | Janney | Neutral → Buy |
| 2022-10-14 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-03 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Herabstufung | Goldman | Buy → Neutral |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-04-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-01 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-04 | Eingeleitet | Raymond James | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-03-29 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-14 | Eingeleitet | Goldman | Neutral |
| 2020-09-14 | Eingeleitet | Jefferies | Buy |
| 2020-09-14 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Harmony Biosciences Holdings Inc Aktie (HRMY) Neueste Nachrichten
Earnings Beat: Is Harmony Biosciences Holdings Inc part of any ETF2025 Key Highlights & AI Powered Market Trend Analysis - baoquankhu1.vn
Harmony Biosciences Projects WAKIX Revenue to Surpass $1 Billion in 2026 - Sleep Review
Harmony Biosciences stock drops after ZYN002 exit as 2026 Wakix sales outlook tops $1 billion - TechStock²
HRMY: WAKIX nears blockbuster status as pipeline and commercial expansion drive growth into 2026 - TradingView — Track All Markets
Harmony Biosciences (NASDAQ:HRMY) Stock Price Down 7.4%Here's Why - MarketBeat
Harmony Biosciences (HRMY) is an Incredible Growth Stock: 3 Reasons Why - Yahoo Finance
Buy Signal: Is Harmony Biosciences Holdings Inc. stock a buy before product launchesEarnings Miss & Precise Entry and Exit Recommendations - Bộ Nội Vụ
Harmony Biosciences projects 2026 WAKIX revenue to exceed $1 billion By Investing.com - Investing.com Nigeria
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $37 at Goldman Sachs - StreetInsider
Harmony Biosciences forecasts WAKIX revenue to exceed $1 billion in 2026 - StreetInsider
Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation - Business Wire
J.P. Morgan Healthcare Conference - MarketScreener
Harmony Biosciences Holdings, Inc. (HRMY) Tops Q4 Earnings and Revenue Estimates - MSN
Harmony Biosciences' chief commercial officer sells $551,575 in stock - MSN
Is Harmony Biosciences Holdings Inc. stock positioned well for digital economy2025 AllTime Highs & Verified Stock Trade Ideas - Улправда
Is Harmony Biosciences (HRMY) Pricing Reflect Future Growth After Recent Mixed Share Performance - Yahoo Finance
How to contact the Daily Bulletin - FinancialContent
Assessing Harmony Biosciences (HRMY) Valuation After Fresh Clinical Trial Progress In Rare Neurological Disorders - Sahm
Will Harmony Biosciences Holdings Inc. stock outperform growth indexesNew Guidance & Weekly High Conviction Ideas - ulpravda.ru
Why Harmony Biosciences Holdings Inc. stock attracts high net worth investorsWeekly Trend Recap & Short-Term Trading Alerts - Улправда
Bank Watch: Is Harmony Biosciences Holdings Inc. stock positioned well for digital economyEarnings Performance Report & Fast Exit Strategy with Risk Control - Улправда
Market Wrap: Why Harmony Biosciences Holdings Inc. stock attracts high net worth investorsTrade Ideas & Reliable Price Breakout Signals - Улправда
6 Analysts Have This To Say About Harmony Biosciences Hldgs - Benzinga
Are Strong Financial Prospects The Force That Is Driving The Momentum In Harmony Biosciences Holdings, Inc.'s NASDAQ:HRMY) Stock? - 富途牛牛
Truist Securities Lowers Price Target for HRMY Amidst Current Buy Rating | HRMY Stock News - GuruFocus
HRMY vs. LQDA: Which Stock Is the Better Value Option? - Yahoo Finance
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now? - Yahoo Finance
Harmony Biosciences Holdings, Inc.Common Stock (NQ: HRMY - FinancialContent
Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - Investing News Network
Oklahoma City NewsThe Oklahoman - FinancialContent
Harmony Biosciences Holdings (HRMY) Stock Analysis: A Revenue Growth Powerhouse with 25.66% Upside Potential - DirectorsTalk Interviews
Harmony Biosciences Launches Early Trial of Promising Orexin Agonist - MSN
Market Might Still Lack Some Conviction On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Even After 26% Share Price Boost - 富途牛牛
Top 5 US Stocks To Buy In January 2026 - Investing.com
(HRMY) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
26,279 Shares in Harmony Biosciences Holdings, Inc. $HRMY Acquired by Paradiem LLC - MarketBeat
Exchange Traded Concepts LLC Buys 32,923 Shares of Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences Holdings Inc Stock Analysis and ForecastContrarian Investment Ideas & Big Gains Small Trading - earlytimes.in
Quarterly Trades: What is the fair value of Harmony Biosciences Holdings Inc stock nowTrade Risk Summary & Daily Oversold Stock Bounce Ideas - Bộ Nội Vụ
Why Harmony Biosciences Holdings Inc. stock is popular among millennials2025 Growth vs Value & Daily Market Momentum Tracking - Улправда
Price-Driven Insight from (HRMY) for Rule-Based Strategy - Stock Traders Daily
Can Harmony Biosciences Holdings Inc. stock maintain operating marginsJuly 2025 Gainers & Reliable Volume Spike Alerts - Улправда
Harmony’s Epilepsy Drug Cuts Seizures in Half in Key Late-Stage Study - MyChesCo
Why Harmony Biosciences Holdings Inc. stock appeals to dividend seekersJuly 2025 Outlook & Verified Chart Pattern Trade Signals - DonanımHaber
Will Harmony Biosciences Holdings Inc. stock outperform value stocksBull Run & Safe Entry Momentum Tips - Улправда
Downgrade Watch: Is Harmony Biosciences Holdings Inc. stock positioned well for digital economyWatch List & Stepwise Swing Trade Plans - DonanımHaber
Dow Update: Will Harmony Biosciences Holdings Inc. stock outperform Dow Jones indexWeekly Trend Summary & Long-Term Growth Plans - Улправда
How sustainable is Harmony Biosciences Holdings Inc. stock dividend payoutEarnings Growth Summary & Trade Opportunity Analysis Reports - Улправда
Is Harmony Biosciences Holdings Inc. stock resilient to inflation2025 Winners & Losers & Community Consensus Trade Signals - Улправда
Harmony Biosciences (NASDAQ:HRMY) Trading Down 3.9% After Insider Selling - MarketBeat
Street Watch: Will Harmony Biosciences Holdings Inc. stock outperform international peersJuly 2025 Analyst Calls & Expert Verified Stock Movement Alerts - Улправда
Finanzdaten der Harmony Biosciences Holdings Inc-Aktie (HRMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.73%
0.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):